KOLH, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et pathologiques ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
Björck, M., Earnshaw, J.J., Acosta, S., Bastos Gonçalves, F., Cochennec, F., Debus, E.S., et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg 59 (2020), 173–218.
Wanhainen, A., Verzini, F., Van Herzeele, I., Allaire, E., Bown, M., Cohnert, T., et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur J Vasc Endovasc Surg 57 (2019), 8–93.
Heit, J.A., Spencer, F.A., White, R.H., The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41 (2016), 3–14.
Spencer, F.A., Emery, C., Joffe, S.W., Pacifico, L., Lessard, D., Reed, G., et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 28 (2009), 401–409.
Baekgaard, N., Incidence and location of deep vein thrombosis in the lower extremities: what do we know?. Plebolymphology 24 (2017), 97–104.
Silverstein, M.D., Heit, J.A., Mohr, D.N., Petterson, T.M., O'Fallon, W.M., Melton, L.J. III, Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 (1998), 585–593.
Roach, R.E., Cannegieter, S.C., Lijfering, W.M., Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment. J Thromb Haemost 12 (2014), 1593–1600.
Bell, E.J., Lutsey, P.L., Basu, S., Cushman, M., Heckbert, S.R., Lloyd-Jones, D.M., et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med 129 (2016), 339.e19–339.e26.
Dentali, F., Ageno, W., Rancan, E., Donati, A.V., Galli, L., Squizzato, A., et al. Seasonal and monthly variability in the incidence of venous thromboembolism. A systematic review and a meta-analysis of the literature. Thromb Haemost 106 (2011), 439–447.
Khan, F., Rahman, A., Carrier, M., Kearon, C., Weitz, J.I., Schulman, S., et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ, 366, 2019, l4363.
Heit, J.A., Ashrani, A., Crusan, D.J., McBane, R.D., Petterson, T.M., Bailey, K.R., Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost 117 (2017), 390–400.
Braithwaite, I., Healy, B., Cameron, L., Weatherall, M., Beasley, R., Venous thromboembolism risk associated with protracted work- and computer-related seated immobility: a case–control study. JRSM Open, 7, 2016, 2054270416632670.
Franchini, M., Mannucci, P.M., ABO blood group and thrombotic vascular disease. Thromb Haemost 112 (2014), 1103–1109.
Olaf, M., Cooney, R., Deep venous thrombosis. Emerg Med Clin North Am 35 (2017), 743–770.
Gaertner, S., Cordeanu, E.M., Mirea, C., Frantz, A.S., Auger, C., Bilbault, P., et al. Increased risk and severity of unprovoked venous thromboembolism with clustering cardiovascular risk factors for atherosclerosis: results of the REMOTEV registry. Int J Cardiol 252 (2018), 169–174.
Pabinger, I., van Es, N., Heinze, G., Posch, F., Riedl, J., Reitter, E.M., et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 5 (2018), e289–e298.
Lee, B.B., Nicolaides, A.N., Myers, K., Meissner, M., Kalodiki, E., Allegra, C., et al. Venous hemodynamic changes in lower limb venous disease: the UIP consensus according to scientific evidence. Int Angiol 35 (2016), 236–352.
Kahn, S.R., Comerota, A.J., Cushman, M., Evans, N.S., Ginsberg, J.S., Goldenberg, N.A., et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 130 (2014), 1636–1661.
Meissner, M.H., The clinical presentation and natural history of acute deep venous thrombosis. Gloviczki, P., (eds.) Handbook of venous and lymphatic disorders, 4th edn., 2017, CRC Press, Boca Raton, FL, 205–219.
Partsch, H., Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. Vasa 30 (2001), 195–204.
De Maeseneer, M.G., Bochanen, N., van Rooijen, G., Neglen, P., Analysis of 1,338 patients with acute lower limb deep venous thrombosis (DVT) supports the inadequacy of the term "proximal DVT". Eur J Vasc Endovasc Surg 51 (2016), 415–420.
Barco, S., Woersching, A.L., Spyropoulos, A.C., Piovella, F., Mahan, C.E., European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 115 (2016), 800–808.
Grosse, S.D., Nelson, R.E., Nyarko, K.A., Richardson, L.C., Raskob, G.E., The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res 137 (2016), 3–10.
Goodacre, S., Sampson, F., Stevenson, M., Wailoo, A., Sutton, A., Thomas, S., et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technol Assess 10 (2006), 1–168.
Stevens, S.M., Ageno, W., Review: the Wells rule is more useful than individual clinical features for predicting risk of deep venous thrombosis. Evid Based Med, 11, 2006, 56.
Wells, P.S., Owen, C., Doucette, S., Fergusson, D., Tran, H., Does this patient have deep vein thrombosis?. JAMA 295 (2006), 199–207.
Geersing, G.J., Zuithoff, N.P., Kearon, C., Anderson, D.R., Ten Cate-Hoek, A.J., Elf, J.L., et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 348, 2014, g1340.
Stein, P.D., Hull, R.D., Patel, K.C., Olson, R.E., Ghali, W.A., Brant, R., et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 140 (2004), 589–602.
Bernardi, E., Camporese, G., Diagnosis of deep-vein thrombosis. Thromb Res 163 (2018), 201–206.
Parry, B.A., Chang, A.M., Schellong, S.M., House, S.L., Fermann, G.J., Deadmon, E.K., International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs. Thromb Res 166 (2018), 63–70.
Needleman, L., Cronan, J.J., Lilly, M.P., Merli, G.J., Adhikari, S., Hertzberg, B.S., et al. Ultrasound for lower extremity deep venous thrombosis: multidisciplinary recommendations from the Society of Radiologists in Ultrasound Consensus Conference. Circulation 137 (2018), 1505–1515.
Gibson, N.S., Schellong, S.M., Kheir, D.Y., Beyer-Westendorf, J., Gallus, A.S., McRae, S., et al. Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis: a prospective management study. J Thromb Haemost 7 (2009), 2035–2041.
Cogo, A., Lensing, A.W., Koopman, M.M., Piovella, F., Siragusa, S., Wells, P.S., et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ 316 (1998), 17–20.
Schellong, S.M., Schwarz, T., Halbritter, K., Beyer, J., Siegert, G., Oettler, W., et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 89 (2003), 228–234.
Righini, M., Paris, S., Le Gal, G., Laroche, J.P., Perrier, A., Bounameaux, H., Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemost 95 (2006), 56–64.
Ageno, W., Camporese, G., Riva, N., Iotti, M., Bucherini, E., Righini, M., et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol 2 (2015), e474–e480.
Karande, G.Y., Hedgire, S.S., Sanchez, Y., Baliyan, V., Mishra, V., Ganguli, S., et al. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther 6 (2016), 493–507.
Sampson, F.C., Goodacre, S.W., Thomas, S.M., van Beek, E.J., The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol 17 (2007), 175–181.
Mendichovszky, I.A., Priest, A.N., Bowden, D.J., Hunter, S., Joubert, I., Hilborne, S., et al. Combined MR direct thrombus imaging and non-contrast magnetic resonance venography reveal the evolution of deep vein thrombosis: a feasibility study. Eur Radiol 27 (2017), 2326–2332.
van Dam, L.F., Dronkers, C.E.A., Gautam, G., Eckerbom, A., Ghanima, W., Gleditsch, J., et al. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. Blood 135 (2020), 1377–1385.
Kelly, J., Hunt, B.J., The utility of pretest probability assessment in patients with clinically suspected venous thromboembolism. J Thromb Haemost 1 (2003), 1888–1896.
Dronkers, C.E., Klok, F.A., Huisman, M.V., Current and future perspectives in imaging of venous thromboembolism. J Thromb Haemost 14 (2016), 1696–1710.
Jenkins, J.S., Endovascular therapies to treat iliofemoral deep venous thrombosis. Prog Cardiovasc Dis 54 (2011), 70–76.
Kearon, C., Ageno, W., Cannegieter, S.C., Cosmi, B., Geersing, G.J., Kyrle, P.A., et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 14 (2016), 1480–1483.
Avnery, O., Martin, M., Bura-Riviere, A., Barillari, G., Mazzolai, L., Mahe, I., et al. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med 287 (2020), 32–41.
Kearon, C., Parpia, S., Spencer, F.A., Schulman, S., Stevens, S.M., Shah, V., et al. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results: a cohort study. J Thromb Haemost 17 (2019), 1144–1152.
Blanco-Molina, A., Trujillo-Santos, J., Pesavento, R., Rosa, V., Falga, C., Tolosa, C., et al. Outcome after discontinuing anticoagulant therapy in women with venous thromboembolism during hormonal use. Thromb Res, 151(Suppl. 1), 2017 S6–10.
Baglin, T., Luddington, R., Brown, K., Baglin, C., Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362 (2003), 523–526.
Stein, P.D., Matta, F., Musani, M.H., Diaczok, B., Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med 123 (2010), 426–431.
Tzoran, I., Saharov, G., Brenner, B., Delsart, D., Roman, P., Visona, A., et al. Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs. J Thromb Haemost 10 (2012), 564–571.
Garcia-Fuster, M.J., Fabia, M.J., Furio, E., Pichler, G., Redon, J., Forner, M.J., et al. Should we look for silent pulmonary embolism in patients with deep venous thrombosis?. BMC Cardiovasc Disord, 14, 2014, 178.
Hughes, M.J., Stein, P.D., Matta, F., Silent pulmonary embolism in patients with distal deep venous thrombosis: systematic review. Thromb Res 134 (2014), 1182–1185.
Monreal, M., Ruiz, J., Fraile, M., Bonet, M., Davant, E., Muchart, J., et al. Prospective study on the usefulness of lung scan in patients with deep vein thrombosis of the lower limbs. Thromb Haemost 85 (2001), 771–774.
Girard, P., Decousus, M., Laporte, S., Buchmuller, A., Herve, P., Lamer, C., et al. Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. Am J Respir Crit Care Med 164 (2001), 1033–1037.
Prandoni, P., Lensing, A.W., Buller, H.R., Cogo, A., Prins, M.H., Cattelan, A.M., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327 (1992), 1128–1133.
Zhou, M., Zhang, L., Ding, Y., Wang, Y., Yan, D., Lin, C., et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: a meta-analysis. Thromb Res 157 (2017), 147–153.
Klein, A., Shepshelovich, D., Spectre, G., Goldvaser, H., Raanani, P., Gafter-Gvili, A., Screening for occult cancer in idiopathic venous thromboembolism – systemic review and meta-analysis. Eur J Intern Med 42 (2017), 74–80.
Delluc, A., Ianotto, J.C., Tromeur, C., De Moreuil, C., Couturaud, F., Lacut, K., et al. Real-world incidence of cancer following a first unprovoked venous thrombosis: results from the EPIGETBO study. Thromb Res 164 (2018), 79–84.
Jara-Palomares, L., Otero, R., Jimenez, D., Carrier, M., Tzoran, I., Brenner, B., et al. Development of a risk prediction score for occult cancer in patients with VTE. Chest 151 (2017), 564–571.
Kleinjan, A., van Doormaal, F.F., Prins, M.H., Buller, H.R., Otten, J.M., Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med 70 (2012), 311–317.
Robertson, L., Yeoh, S.E., Broderick, C., Stansby, G., Agarwal, R., Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database Syst Rev, 11, 2018, CD010837.
Baglin, T., Gray, E., Greaves, M., Hunt, B.J., Keeling, D., Machin, S., et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 149 (2010), 209–220.
National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (clinical guideline 144). Available at: www.nice.org.uk/guidance/cg144.
Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, 2012 e419S–96S.
Barnes GD. Thrombophilia testing for provoked VTE. Available at: https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/06/05/12/46/thrombophilia-testing-in-provoked-venous-thromboembolism.
Heit, J.A., Armasu, S.M., McCauley, B.M., Kullo, I.J., Sicotte, H., Pathak, J., et al. Identification of unique venous thromboembolism-susceptibility variants in African-Americans. Thromb Haemost 117 (2017), 758–768.
Jiang, J., Jiao, Y., Ding, X., Zhang, B., Association between genetic polymorphisms and deep vein thrombosis in a Chinese population. Thromb Res 136 (2015), 687–689.
Corban, M.T., Duarte-Garcia, A., McBane, R.D., Matteson, E.L., Lerman, L.O., Lerman, A., Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J Am Coll Cardiol 69 (2017), 2317–2330.
Tektonidou, M.G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78 (2019), 1296–1304.
Legault, K., Schunemann, H., Hillis, C., Yeung, C., Akl, E.A., Carrier, M., et al. McMaster RARE – Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost 16 (2018), 1656–1664.
Hill, A., Kelly, R.J., Hillmen, P., Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 121 (2013), 4985–4996.
Patriquin, C.J., Kiss, T., Caplan, S., Chin-Yee, I., Grewal, K., Grossman, J., et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. Eur J Haematol 102 (2019), 36–52.
National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (clinical guideline 89). Available at: www.nice.org.uk/guidance/cg89.
Stevens, S.M., Woller, S.C., Bauer, K.A., Kasthuri, R., Cushman, M., Streiff, M., et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 41 (2016), 154–164.
Connors, J.M., Thrombophilia testing and venous thrombosis. N Engl J Med 377 (2017), 1177–1187.
Garcia-Horton, A., Kovacs, M.J., Abdulrehman, J., Taylor, J.E., Sharma, S., Lazo-Langner, A., Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res 149 (2017), 76–80.
Schreiber, K., Sciascia, S., de Groot, P.G., Devreese, K., Jacobsen, S., Ruiz-Irastorza, G., et al. Antiphospholipid syndrome. Nat Rev Dis Primers, 4, 2018, 17103.
Devreese, K.M.J., Ortel, T.L., Pengo, V., de Laat, B., Subcommittee on Lupus Anticoagulant/Antiphospholipid A. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 16 (2018), 809–813.
Kearon, C., Akl, E.A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 149 (2016), 315–352.
Mazzolai, L., Aboyans, V., Ageno, W., Agnelli, G., Alatri, A., Bauersachs, R., et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 39 (2018), 4208–4218.
Hirsh, J., Bauer, K.A., Donati, M.B., Gould, M., Samama, M.M., Weitz, J.I., Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 2008 141S–59S.
Bauersachs, R.M., Neue antikoaguanzien [New anticoagulants]. Hamostaseologie 28 (2008), 21–26.
Smythe, M.A., Priziola, J., Dobesh, P.P., Wirth, D., Cuker, A., Wittkowsky, A.K., Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 41 (2016), 165–186.
Hull, R.D., Raskob, G.E., Hirsh, J., Jay, R.M., Leclerc, J.R., Geerts, W.H., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315 (1986), 1109–1114.
Samama, M.M., Poller, L., Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 15 (1995), 119–123.
Bauersachs, R.M., Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups. Eur J Intern Med 25 (2014), 600–606.
Palareti, G., Antonucci, E., Mastroiacovo, D., Ageno, W., Pengo, V., Poli, D., et al. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. J Thromb Haemost 16 (2018), 1994–2002.
Schulman, S., Beyth, R.J., Kearon, C., Levine, M.N., Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 2008 257S–98S.
van Es, N., Coppens, M., Schulman, S., Middeldorp, S., Buller, H.R., Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124 (2014), 1968–1975.
Holster, I.L., Valkhoff, V.E., Kuipers, E.J., Tjwa, E.T., New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 145 (2013), 105–112.
Chai-Adisaksopha, C., Crowther, M., Isayama, T., Lim, W., The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124 (2014), 2450–2458.
Budnitz, D.S., Lovegrove, M.C., Shehab, N., Richards, C.L., Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365 (2011), 2002–2012.
Holbrook, A., Schulman, S., Witt, D.M., Vandvik, P.O., Fish, J., Kovacs, M.J., et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, 2012 e152S–84S.
Crowther, M.A., Ageno, W., Garcia, D., Wang, L., Witt, D.M., Clark, N.P., et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 150 (2009), 293–300.
Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol 154 (2011), 311–324.
Majeed, A., Meijer, K., Larrazabal, R., Arnberg, F., Luijckx, G.J., Roberts, R.S., et al. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost 111 (2014), 233–239.
Boer, C., Meesters, M.I., Veerhoek, D., Vonk, A.B.A., Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth 120 (2018), 914–927.
Dhakal, P., Rayamajhi, S., Verma, V., Gundabolu, K., Bhatt, V.R., Reversal of anticoagulation and management of bleeding in patients on anticoagulants. Clin Appl Thromb Hemost 23 (2017), 410–415.
Garcia, D.A., Baglin, T.P., Weitz, J.I., Samama, M.M., Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, 2012 e24S–43S.
Greinacher, A., Thiele, T., Selleng, K., Reversal of anticoagulants: an overview of current developments. Thromb Haemost 113 (2015), 931–942.
Pollack, C.V. Jr., Reilly, P.A., van Ryn, J., Eikelboom, J.W., Glund, S., Bernstein, R.A., et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med 377 (2017), 431–441.
Connolly, S.J., Crowther, M., Eikelboom, J.W., Gibson, C.M., Curnutte, J.T., Lawrence, J.H., et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380 (2019), 1326–1335.
Schulman, S., Gross, P.L., Ritchie, B., Nahirniak, S., Lin, Y., Lieberman, L., et al. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb Haemost 118 (2018), 842–851.
Steffel, J., Verhamme, P., Potpara, T.S., Albaladejo, P., Antz, M., Desteghe, L., et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39 (2018), 1330–1393.
Bakchoul, T., Greinacher, A., Warkentin, T.E., Heparin-induced thrombocytopenia in 2017 and beyond. Thromb Haemost 116 (2016), 781–782.
Linkins, L.A., Dans, A.L., Moores, L.K., Bona, R., Davidson, B.L., Schulman, S., et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, 2012 e495S–530S.
Warkentin, T.E., Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost 116 (2016), 813–822.
Cuker, A., Gimotty, P.A., Crowther, M.A., Warkentin, T.E., Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 120 (2012), 4160–4167.
Cuker, A., Management of the multiple phases of heparin-induced thrombocytopenia. Thromb Haemost 116 (2016), 835–842.
Nagler, M., Bakchoul, T., Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 116 (2016), 823–834.
Lobo, B., Finch, C., Howard, A., Minhas, S., Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 99 (2008), 208–214.
Warkentin, T.E., Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – bridging the River Coumarin. Thromb Haemost 99 (2008), 2–3.
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 (1996), 677–681.
Koopman, M.M., Prandoni, P., Piovella, F., Ockelford, P.A., Brandjes, D.P., van der Meer, J., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 334 (1996), 682–687.
Othieno, R., Okpo, E., Forster, R., Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev, 1, 2018, CD003076.
Nicolaides, A.N., Fareed, J., Kakkar, A.K., Comerota, A.J., Goldhaber, S.Z., Hull, R., et al. Prevention and treatment of venous thromboembolism – International Consensus Statement. Int Angiol 32 (2013), 111–260.
Kearon, C., Iorio, A., Palareti, G., Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost 8 (2010), 2313–2315.
Iorio, A., Kearon, C., Filippucci, E., Marcucci, M., Macura, A., Pengo, V., et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170 (2010), 1710–1716.
The Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
Weitz, J.I., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T.A., Cohen, A.T., et al. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost 114 (2015), 645–650.
Prins, M.H., Lensing, A.W.A., Prandoni, P., Wells, P.S., Verhamme, P., Beyer-Westendorf, J., et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv 2 (2018), 788–796.
Boutitie, F., Pinede, L., Schulman, S., Agnelli, G., Raskob, G., Julian, J., et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ, 342, 2011, d3036.
Kearon, C., Ginsberg, J.S., Anderson, D.R., Kovacs, M.J., Wells, P., Julian, J.A., et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2 (2004), 743–749.
Levine, M.N., Hirsh, J., Gent, M., Turpie, A.G., Weitz, J., Ginsberg, J., et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74 (1995), 606–611.
Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I., et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103 (2001), 2453–2460.
Schulman, S., Rhedin, A.S., Lindmarker, P., Carlsson, A., Larfars, G., Nicol, P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332 (1995), 1661–1665.
Andras, A., Sala Tenna, A., Stewart, M., Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev, 7, 2017, CD002001.
Kakkos, S.K., Kirkilesis, G.I., Tsolakis, I.A., Editor's Choice – efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 48 (2014), 565–575.
Agnelli, G., Buller, H.R., Cohen, A., Curto, M., Gallus, A.S., Johnson, M., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369 (2013), 1406–1415.
Schulman, S., Kearon, C., Kakkar, A.K., Mismetti, P., Schellong, S., Eriksson, H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (2009), 2342–2352.
Schulman, S., Kakkar, A.K., Goldhaber, S.Z., Schellong, S., Eriksson, H., Mismetti, P., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129 (2014), 764–772.
Cohen, A.T., Hamilton, M., Mitchell, S.A., Phatak, H., Liu, X., Bird, A., et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One, 10, 2015, e0144856.
van der Wall, S.J., van der Pol, L.M., Ende-Verhaar, Y.M., Cannegieter, S.C., Schulman, S., Prandoni, P., et al. Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. Eur Respir Rev, 27, 2018, 180094.
Agnelli, G., Prandoni, P., Santamaria, M.G., Bagatella, P., Iorio, A., Bazzan, M., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345 (2001), 165–169.
Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M.J., Anderson, D.R., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999), 901–907.
Brighton, T.A., Eikelboom, J.W., Mann, K., Mister, R., Gallus, A., Ockelford, P., et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 367 (2012), 1979–1987.
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 366 (2012), 1959–1967.
Agnelli, G., Buller, H.R., Cohen, A., Curto, M., Gallus, A.S., Johnson, M., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368 (2013), 699–708.
Schulman, S., Kearon, C., Kakkar, A.K., Schellong, S., Eriksson, H., Baanstra, D., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368 (2013), 709–718.
Marik, P.E., Cavallazzi, R., Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PLoS One, 10, 2015, e0143252.
Vasanthamohan, L., Boonyawat, K., Chai-Adisaksopha, C., Crowther, M., Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 16 (2018), 1288–1295.
Lijfering, W.M., Timp, J.F., Cannegieter, S.C., Predicting the risk of recurrent venous thrombosis: what the future might bring. J Thromb Haemost 17 (2019), 1522–1526.
Ensor, J., Riley, R.D., Moore, D., Snell, K.I., Bayliss, S., Fitzmaurice, D., Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open, 6, 2016, e011190.
Rodger, M.A., Kahn, S.R., Wells, P.S., Anderson, D.A., Chagnon, I., Le Gal, G., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179 (2008), 417–426.
Eichinger, S., Heinze, G., Jandeck, L.M., Kyrle, P.A., Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121 (2010), 1630–1636.
Tosetto, A., Iorio, A., Marcucci, M., Baglin, T., Cushman, M., Eichinger, S., et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 10 (2012), 1019–1025.
Marcucci, M., Iorio, A., Douketis, J.D., Eichinger, S., Tosetto, A., Baglin, T., et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. J Thromb Haemost 13 (2015), 775–781.
Rodger, M.A., Le Gal, G., Anderson, D.R., Schmidt, J., Pernod, G., Kahn, S.R., et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ, 356, 2017, j1065.
Shaw, J., de Wit, C., Le Gal, G., Carrier, M., Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease. J Thromb Haemost 15 (2017), 925–930.
Shaw, J.R., Douketis, J., Le Gal, G., Carrier, M., Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: an analysis of thrombotic and bleeding outcomes. J Thromb Haemost 17 (2019), 1171–1178.
Douketis, J.D., Spyropoulos, A.C., Kaatz, S., Becker, R.C., Caprini, J.A., Dunn, A.S., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373 (2015), 823–833.
Weitz, J.I., Lensing, A.W.A., Prins, M.H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 376 (2017), 1211–1222.
Meissner, M.H., Duplex follow-up of patients with DVT: does it have clinical significance?. Semin Vasc Surg 14 (2001), 215–221.
Ascher, E., Depippo, P.S., Hingorani, A., Yorkovich, W., Salles-Cunha, S., Does repeat duplex ultrasound for lower extremity deep vein thrombosis influence patient management?. Vasc Endovascular Surg 38 (2004), 525–531.
Prandoni, P., Lensing, A.W., Prins, M.R., Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc Med 3 (1998), 57–60.
Andreozzi, G.M., Bignamini, A.A., Davi, G., Palareti, G., Matuska, J., Holy, M., et al. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation 132 (2015), 1891–1897.
Kyrle, P.A., How I treat recurrent deep-vein thrombosis. Blood 127 (2016), 696–702.
Schulman, S., How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood 129 (2017), 3285–3293.
Piran, S., Schulman, S., Management of recurrent venous thromboembolism in patients with cancer: a review. Thromb Res 164:Suppl. 1 (2018), S172–S177.
Schulman, S., Granqvist, S., Holmstrom, M., Carlsson, A., Lindmarker, P., Nicol, P., et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 336 (1997), 393–398.
Siragusa, S., Malato, A., Anastasio, R., Cigna, V., Milio, G., Amato, C., et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 112 (2008), 511–515.
Siragusa, S., Malato, A., Saccullo, G., Iorio, A., Di Ianni, M., Caracciolo, C., et al. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. Am J Hematol 86 (2011), 914–917.
Carrier, M., Rodger, M.A., Wells, P.S., Righini, M., Gal, G.L.E., Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 9 (2011), 1119–1125.
Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355 (2006), 1780–1789.
Prandoni, P., Vedovetto, V., Ciammaichella, M., Bucherini, E., Corradini, S., Enea, I., et al. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis. Thromb Res 154 (2017), 35–41.
Palareti, G., Cosmi, B., Legnani, C., Antonucci, E., De Micheli, V., Ghirarduzzi, A., et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 124 (2014), 196–203.
Prandoni, P., Lensing, A.W., Prins, M.H., Pesavento, R., Piccioli, A., Sartori, M.T., et al. The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. Semin Thromb Hemost 41 (2015), 133–140.
Turner, T.E., Saeed, M.J., Novak, E., Brown, D.L., Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality. JAMA Netw Open, 1, 2018, e180452.
Prepic Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112 (2005), 416–422.
Sharifi, M., Bay, C., Skrocki, L., Lawson, D., Mazdeh, S., Role of IVC filters in endovenous therapy for deep venous thrombosis: The FILTER-PEVI (Filter Implantation to Lower Thromboembolic Risk in Percutaneous Endovenous Intervention) trial. Catheter Cardiovasc Interv 35 (2012), 1408–1413.
Kahn, S.R., Shapiro, S., Ducruet, T., Wells, P.S., Rodger, M.A., Kovacs, M.J., et al. Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost 112 (2014), 1137–1141.
Prandoni, P., Lensing, A.W., Prins, M.H., Frulla, M., Marchiori, A., Bernardi, E., et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141 (2004), 249–256.
Ten Cate-Hoek, A.J., Amin, E.E., Bouman, A.C., Meijer, K., Tick, L.W., Middeldorp, S., et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol 5 (2018), e25–33.
Partsch, H., Kaulich, M., Mayer, W., Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome. Int Angiol 23 (2004), 206–212.
Prandoni, P., Noventa, F., Quintavalla, R., Bova, C., Cosmi, B., Siragusa, S., et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood 119 (2012), 1561–1565.
Gloviczki, P., Comerota, A.J., Dalsing, M.C., Eklof, B.G., Gillespie, D.L., Gloviczki, M.L., et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 53 (2011), 2S–48S.
Flour, M., Clark, M., Partsch, H., Mosti, G., Uhl, J.F., Chauveau, M., et al. Dogmas and controversies in compression therapy: report of an International Compression Club (ICC) meeting, Brussels, May 2011. Int Wound J 10 (2013), 516–526.
Partsch, H., Blattler, W., Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 32 (2000), 861–869.
Roumen-Klappe, E.M., den Heijer, M., van Rossum, J., Wollersheim, H., van der Vleuten, C., Thien, T., et al. Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome. J Thromb Thrombolysis 27 (2009), 400–405.
Arpaia, G., Cimminiello, C., Mastrogiacomo, O., de Gaudenzi, E., Efficacy of elastic compression stockings used early or after resolution of the edema on recanalization after deep venous thrombosis: the COM.PRE Trial. Blood Coagul Fibrinolysis 18 (2007), 131–137.
Amin, E.E., Bistervels, I.M., Meijer, K., Tick, L.W., Middeldorp, S., Mostard, G., et al. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood 132 (2018), 2298–2304.
Amin, E.E., Joore, M.A., Ten Cate, H., Meijer, K., Tick, L.W., Middeldorp, S., et al. Clinical and economic impact of compression in the acute phase of deep vein thrombosis. J Thromb Haemost 16 (2018), 1555–1563.
Donadini, M.P., Ageno, W., Antonucci, E., Cosmi, B., Kovacs, M.J., Le Gal, G., et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost 111 (2014), 172–179.
Prandoni, P., Lensing, A.W., Cogo, A., Cuppini, S., Villalta, S., Carta, M., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996), 1–7.
Prandoni, P., Kahn, S.R., Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 145 (2009), 286–295.
Kahn, S.R., Shrier, I., Julian, J.A., Ducruet, T., Arsenault, L., Miron, M.J., et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 149 (2008), 698–707.
Saarinen, J., Kallio, T., Lehto, M., Hiltunen, S., Sisto, T., The occurrence of the post-thrombotic changes after an acute deep venous thrombosis. A prospective two-year follow-up study. J Cardiovasc Surg (Torino) 41 (2000), 441–446.
Villalta, S.B.P., Picolli, A., Lensing, A., Prins, M., Prandoni, P., Assessment of validity and reproducibility of a clinical scale for the post thrombotic syndrome. Haemostasis, 24, 1994, 157.
Kahn, S.R., Hirsch, A., Shrier, I., Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 162 (2002), 1144–1148.
Bergqvist, D., Jendteg, S., Johansen, L., Persson, U., Odegaard, K., Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 126 (1997), 454–457.
Lubberts, B., Paulino Pereira, N.R., Kabrhel, C., Kuter, D.J., DiGiovanni, C.W., What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis. Thromb Haemost 116 (2016), 417–431.
Strandness, D.E. Jr., Langlois, Y., Cramer, M., Randlett, A., Thiele, B.L., Long-term sequelae of acute venous thrombosis. JAMA 250 (1983), 1289–1292.
Tick, L.W., Kramer, M.H., Rosendaal, F.R., Faber, W.R., Doggen, C.J., Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost 6 (2008), 2075–2081.
Galanaud, J.P., Holcroft, C.A., Rodger, M.A., Kovacs, M.J., Betancourt, M.T., Wells, P.S., et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. J Thromb Haemost 11 (2013), 474–480.
Stain, M., Schonauer, V., Minar, E., Bialonczyk, C., Hirschl, M., Weltermann, A., et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost 3 (2005), 2671–2676.
Tick, L.W., Doggen, C.J., Rosendaal, F.R., Faber, W.R., Bousema, M.T., Mackaay, A.J., et al. Predictors of the post-thrombotic syndrome with non-invasive venous examinations in patients 6 weeks after a first episode of deep vein thrombosis. J Thromb Haemost 8 (2010), 2685–2692.
Labropoulos, N., Waggoner, T., Sammis, W., Samali, S., Pappas, P.J., The effect of venous thrombus location and extent on the development of post-thrombotic signs and symptoms. J Vasc Surg 48 (2008), 407–412.
van Dongen, C.J., Prandoni, P., Frulla, M., Marchiori, A., Prins, M.H., Hutten, B.A., Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 3 (2005), 939–942.
Brandjes, D.P., Buller, H.R., Heijboer, H., Huisman, M.V., de Rijk, M., Jagt, H., et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 349 (1997), 759–762.
Kahn, S.R., Shapiro, S., Wells, P.S., Rodger, M.A., Kovacs, M.J., Anderson, D.R., et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 383 (2014), 880–888.
Jayaraj, A., Meissner, M., Impact of graduated compression stockings on the prevention of post-thrombotic syndrome – results of a randomized controlled trial. Phlebology 30 (2015), 541–548.
Appelen, D., van Loo, E., Prins, M.H., Neumann, M.H., Kolbach, D.N., Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev, 9, 2017, CD004174.
Subbiah, R., Aggarwal, V., Zhao, H., Kolluri, R., Chatterjee, S., Bashir, R., Effect of compression stockings on post thrombotic syndrome in patients with deep vein thrombosis: a meta-analysis of randomised controlled trials. Lancet Haematol 3 (2016), e293–300.
Kakkos, S.K., Daskalopoulou, S.S., Daskalopoulos, M.E., Nicolaides, A.N., Geroulakos, G., Review on the value of graduated elastic compression stockings after deep vein thrombosis. Thromb Haemost 96 (2006), 441–445.
Aschwanden, M., Jeanneret, C., Koller, M.T., Thalhammer, C., Bucher, H.C., Jaeger, K.A., Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg 47 (2008), 1015–1021.
Mol, G.C., van de Ree, M.A., Klok, F.A., Tegelberg, M.J., Sanders, F.B., Koppen, S., et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ, 353, 2016, i2691.
Amin, E.E., ten Cate-Hoek, A.J., Bouman, A.C., Meijer, K., Tick, L., Middeldorp, S., et al. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. Lancet Haematol 5 (2018), e512–e519.
ten Cate-Hoek, A.J., Bouman, A.C., Joore, M.A., Prins, M., Ten Cate, H., for the IDEAL DVT Trial investigators. The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. BMJ Open, 4, 2014, e005265.
Ginsberg, J.S., Hirsh, J., Julian, J., Vander LaandeVries, M., Magier, D., MacKinnon, B., et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med 161 (2001), 2105–2109.
Haig, Y., Enden, T., Grotta, O., Klow, N.E., Slagsvold, C.E., Ghanima, W., et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol 3 (2016), e64–71.
Prandoni, P., Frulla, M., Sartor, D., Concolato, A., Girolami, A., Vein abnormalities and the post-thrombotic syndrome. J Thromb Haemost 3 (2005), 401–402.
Plate, G., Eklof, B., Norgren, L., Ohlin, P., Dahlstrom, J.A., Venous thrombectomy for iliofemoral vein thrombosis–10-year results of a prospective randomised study. Eur J Vasc Endovasc Surg 14 (1997), 367–374.
Rodriguez, L.E., Aboukheir-Aboukheir, A., Figueroa-Vicente, R., Soler-Bernardini, H., Bolanos-Avila, G., Torruella-Bartolomei, L.J., et al. Hybrid operative thrombectomy is noninferior to percutaneous techniques for the treatment of acute iliofemoral deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 5 (2017), 177–184.
Foegh, P., Jensen, L.P., Klitfod, L., Broholm, R., Baekgaard, N., Editor's Choice – Factors associated with long-term outcome in 191 patients with ilio-femoral DVT treated with catheter-directed thrombolysis. Eur J Vasc Endovasc Surg 53 (2017), 419–424.
Engelberger, R.P., Stuck, A., Spirk, D., Willenberg, T., Haine, A., Periard, D., et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: 1-year follow-up data of a randomized-controlled trial. J Thromb Haemost 15 (2017), 1351–1360.
Grunwald, M.R., Hofmann, L.V., Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol 15 (2004), 347–352.
Jeyabalan, G., Marone, L., Rhee, R., Hirsch, S., Makaroun, M.S., Cho, J., et al. Inflow thrombosis does not adversely affect thrombolysis outcomes of symptomatic iliofemoral deep vein thrombosis. J Vasc Surg 54 (2011), 448–453.
Enden, T., Haig, Y., Klow, N.E., Slagsvold, C.E., Sandvik, L., Ghanima, W., et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 379 (2012), 31–38.
Vedantham, S., Goldhaber, S.Z., Julian, J.A., Kahn, S.R., Jaff, M.R., Cohen, D.J., et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 377 (2017), 2240–2252.
Baekgaard, N., Klitfod, L., Broholm, R., Safety and efficacy of catheter-directed thrombolysis. Phlebology 27:Suppl. 1 (2012), 149–154.
AbuRahma, A.F., Perkins, S.E., Wulu, J.T., Ng, H.K., Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. Ann Surg 233 (2001), 752–760.
Notten, P., Ten Cate-Hoek, A.J., Arnoldussen, C., Strijkers, R.H.W., de Smet, A., Tick, L.W., et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol 7 (2020), e40–e49.
Protack, C.D., Bakken, A.M., Patel, N., Saad, W.E., Waldman, D.L., Davies, M.G., Long-term outcomes of catheter directed thrombolysis for lower extremity deep venous thrombosis without prophylactic inferior vena cava filter placement. J Vasc Surg 45 (2007), 992–997.
Baekgaard, N., Broholm, R., Just, S., Jorgensen, M., Jensen, L.P., Long-term results using catheter-directed thrombolysis in 103 lower limbs with acute iliofemoral venous thrombosis. Eur J Vasc Endovasc Surg 39 (2010), 112–117.
Garcia, M.J., Lookstein, R., Malhotra, R., Amin, A., Blitz, L.R., Leung, D.A., et al. Endovascular management of deep vein thrombosis with rheolytic thrombectomy: final report of the prospective multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) registry. J Vasc Interv Radiol 26 (2015), 777–785.
Sharifi, M., Bay, C., Mehdipour, M., Sharifi, J., TORPEDO Investigators. Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trial: midterm results. J Endovasc Ther 19 (2012), 273–280.
Enden, T., Wik, H.S., Kvam, A.K., Haig, Y., Klow, N.E., Sandset, P.M., Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. BMJ Open, 3, 2013, e002984.
Enden, T., Resch, S., White, C., Wik, H.S., Klow, N.E., Sandset, P.M., Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. J Thromb Haemost 11 (2013), 1032–1042.
Comerota, A.J., Kearon, C., Gu, C.S., Julian, J.A., Goldhaber, S.Z., Kahn, S.R., et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. Circulation 139 (2019), 1162–1173.
Kearon, C., Gu, C.S., Julian, J.A., Goldhaber, S.Z., Comerota, A.J., Gornik, H.L., et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost 119 (2019), 633–644.
Seager, M.J., Busuttil, A., Dharmarajah, B., Davies, A.H., Editor's Choice – A systematic review of endovenous stenting in chronic venous disease secondary to iliac vein obstruction. Eur J Vasc Endovasc Surg 51 (2016), 100–120.
Eijgenraam, P., ten Cate, H., ten Cate-Hoek, A.J., Venous stenting after deep venous thrombosis and antithrombotic therapy: a systematic review. Rev Vasc Med 2 (2014), 88–97.
Kahn, S.R., Julian, J.A., Kearon, C., Gu, C.S., Cohen, D.J., Magnuson, E.A., et al. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 8 (2020), 8–23.
Galanaud, J.P., Sevestre-Pietri, M.A., Bosson, J.L., Laroche, J.P., Righini, M., Brisot, D., et al. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost 102 (2009), 493–500.
Kitchen, L., Lawrence, M., Speicher, M., Frumkin, K., Emergency department management of suspected calf-vein deep venous thrombosis: a diagnostic algorithm. West J Emerg Med 17 (2016), 384–390.
Bernardi, E., Camporese, G., Buller, H.R., Siragusa, S., Imberti, D., Berchio, A., et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA 300 (2008), 1653–1659.
Garry, J., Duke, A., Labropoulos, N., Systematic review of the complications following isolated calf deep vein thrombosis. Br J Surg 103 (2016), 789–796.
Brateanu, A., Patel, K., Chagin, K., Tunsupon, P., Yampikulsakul, P., Shah, G.V., et al. Probability of developing proximal deep-vein thrombosis and/or pulmonary embolism after distal deep-vein thrombosis. Thromb Haemost 115 (2016), 608–614.
Franco, L., Giustozzi, M., Agnelli, G., Becattini, C., Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemos 15 (2017), 1142–1154.
Lagerstedt, C.I., Olsson, C.G., Fagher, B.O., Oqvist, B.W., Albrechtsson, U., Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2 (1985), 515–518.
Nielsen, H.K., Husted, S.E., Krusell, L.R., Fasting, H., Charles, P., Hansen, H.H., et al. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thromb Res 73 (1994), 215–226.
Ferrara, F., Meli, F., Amato, C., Cospite, V., Raimondi, F., Novo, G., et al. Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins. Angiology 57 (2006), 418–423.
Schwarz, T., Buschmann, L., Beyer, J., Halbritter, K., Rastan, A., Schellong, S., Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. J Vasc Surg 52 (2010), 1246–1250.
Horner, D., Hogg, K., Body, R., Nash, M.J., Baglin, T., Mackway-Jones, K., The anticoagulation of calf thrombosis (ACT) project: results from the randomized controlled external pilot trial. Chest 146 (2014), 1468–1477.
Righini, M., Galanaud, J.P., Guenneguez, H., Brisot, D., Diard, A., Faisse, P., et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol 3 (2016), e556–e562.
Kirkilesis, G., Kakkos, S.K., Bicknell, C., Salim, S., Kakavia, K., Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev, 4, 2020, CD013422.
Sartori, M., Migliaccio, L., Favaretto, E., Palareti, G., Cosmi, B., Two years outcome of isolated distal deep vein thrombosis. Thromb Res 134 (2014), 36–40.
Galanaud, J.P., Sevestre, M.A., Genty, C., Kahn, S.R., Pernod, G., Rolland, C., et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost 12 (2014), 436–443.
Dentali, F., Pegoraro, S., Barco, S., di Minno, M.N.D., Mastroiacovo, D., Pomero, F., et al. Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. J Thromb Haemost 15 (2017), 1757–1763.
Galanaud, J.P., Sevestre, M.A., Pernod, G., Genty, C., Richelet, S., Kahn, S.R., et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost 15 (2017), 907–916.
Chinsakchai, K., Ten Duis, K., Moll, F.L., de Borst, G.J., Trends in management of phlegmasia cerulea dolens. Vasc Endovascular Surg 45 (2011), 5–14.
Patel, N.H., Plorde, J.J., Meissner, M., Catheter-directed thrombolysis in the treatment of phlegmasia cerulea dolens. Ann Vasc Surg 12 (1998), 471–475.
Zhang, X., Chen, Z., Sun, Y., Xu, M., Surgical thrombectomy and simultaneous stenting for phlegmasia cerulea dolens caused by iliac vein occlusion. Ann Vasc Surg 51 (2018), 239–245.
Decousus, H., Quere, I., Presles, E., Becker, F., Barrellier, M.T., Chanut, M., et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 152 (2010), 218–224.
Cosmi, B., Filippini, M., Tonti, D., Avruscio, G., Ghirarduzzi, A., Bucherini, E., et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost 10 (2012), 1026–1035.
Beyer-Westendorf, J., Schellong, S.M., Gerlach, H., Rabe, E., Weitz, J.I., Jersemann, K., et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 4 (2017), e105–e113.
Nikolakopoulos, K.M., Kakkos, S.K., Papageorgopoulou, C.P., Tsolakis, I.A., Extended-duration treatment of superficial vein thrombosis of the lower limbs with tinzaparin. Vasc Specialist Int 34 (2018), 1–9.
Decousus, H., Prandoni, P., Mismetti, P., Bauersachs, R.M., Boda, Z., Brenner, B., et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 363 (2010), 1222–1232.
Galanaud, J.P., Blaise, S., Sevestre, M.A., Terrisse, H., Pernod, G., Gaillard, C., et al. Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thromb Res 171 (2018), 179–186.
Blin, P., Sevestre, M.A., Pouchain, D., Gillet, J.L., Management and 3-month outcomes of isolated superficial vein thrombosis of the lower limb: a real-world cohort study. Thromb Res 157 (2017), 117–119.
Chengelis, D.L., Bendick, P.J., Glover, J.L., Brown, O.W., Ranval, T.J., Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg 24 (1996), 745–749.
Verlato, F., Zucchetta, P., Prandoni, P., Camporese, G., Marzola, M.C., Salmistraro, G., et al. An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. J Vasc Surg 30 (1999), 1113–1115.
Barco, S., Pomero, F., Di Minno, M.N.D., Tamborini Permunian, E., Malato, A., Pasca, S., et al. Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow-up study. J Thromb Haemost 15 (2017), 2176–2183.
Cannegieter, S.C., Horvath-Puho, E., Schmidt, M., Dekkers, O.M., Pedersen, L., Vandenbroucke, J.P., et al. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood 125 (2015), 229–235.
Di Nisio, M., Wichers, I.M., Middeldorp, S., Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev, 2, 2018, CD004982.
Superficial Thrombophlebitis Treated By Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 163 (2003), 1657–1663.
Duffett, L., Kearon, C., Rodger, M., Carrier, M., Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost 119 (2019), 479–489.
Lozano, F.S., Almazan, A., Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovascular Surg 37 (2003), 415–420.
Belcaro, G., Nicolaides, A.N., Errichi, B.M., Cesarone, M.R., De Sanctis, M.T., Incandela, L., et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. Angiology 50 (1999), 523–529.
Gillet, J.L., Allaert, F.A., Perrin, M., Thromboses veineuses superficielles des veines non variqueuses des membres inferieurs. Etude prospective portant sur 42 patients consecutifs. J Mal Vasc 29 (2004), 263–272.
Chopra, R., Leon, L.R., Labropoulos, N., Clinical characteristics and outcomes of patients with multiple simultaneous superficial vein thrombi. J Vasc Surg Venous Lymphat Disord 6 (2018), 485–491.
Lucchi, G., Bilancini, S., Tucci, S., Lucchi, M., Superficial vein thrombosis in non-varicose veins of the lower limbs and thrombophilia. Phlebology 33 (2018), 278–281.
van Doormaal, F.F., Atalay, S., Brouwer, H.J., van der Velde, E.F., Buller, H.R., van Weert, H.C., Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patients. Ann Fam Med 8 (2010), 47–50.
Cosmi, B., Filippini, M., Campana, F., Avruscio, G., Ghirarduzzi, A., Bucherini, E., et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thromb Res 133 (2014), 196–202.
Di Minno, M.N., Ambrosino, P., Ambrosini, F., Tremoli, E., Di Minno, G., Dentali, F., Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 14 (2016), 964–972.
Jorgensen, J.O., Hanel, K.C., Morgan, A.M., Hunt, J.M., The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. J Vasc Surg 18 (1993), 70–73.
van den Houten, M.M., van Grinsven, R., Pouwels, S., Yo, L.S., van Sambeek, M.R., Teijink, J.A., Treatment of upper-extremity outflow thrombosis. Phlebology 31 (2016), 28–33.
Ageno, W., Haas, S., Weitz, J.I., Goldhaber, S.Z., Turpie, A.G.G., Goto, S., et al. Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE registry. Thromb Haemost 119 (2019), 1365–1372.
Thiyagarajah, K., Ellingwood, L., Endres, K., Hegazi, A., Radford, J., Iansavitchene, A., et al. Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: a systematic review and meta-analysis. Thromb Res 174 (2019), 34–39.
Grant, J.D., Stevens, S.M., Woller, S.C., Lee, E.W., Kee, S.T., Liu, D.M., et al. Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thromb Haemost 108 (2012), 1097–1108.
Kucher, N., Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 364 (2011), 861–869.
Sartori, M., Migliaccio, L., Favaretto, E., Cini, M., Legnani, C., Palareti, G., et al. D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis. Thromb Res 135 (2015), 673–678.
Kraaijpoel, N., van Es, N., Porreca, E., Buller, H.R., Di Nisio, M., The diagnostic management of upper extremity deep vein thrombosis: a review of the literature. Thromb Res 156 (2017), 54–59.
Povlsen, S., Povlsen, B., Diagnosing thoracic outlet syndrome: current approaches and future directions. Diagnostics (Basel), 8, 2018, 21.
Baarslag, H.J., Van Beek, E.J., Reekers, J.A., Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience. Acta Radiol 45 (2004), 38–43.
Cote, L.P., Greenberg, S., Caprini, J.A., Tafur, A., Choi, C., Munoz, F.J., et al. Comparisons between upper and lower extremity deep vein thrombosis: a review of the RIETE registry. Clin Appl Thromb Hemost 23 (2017), 748–754.
Montiel, F.S., Ghazvinian, R., Gottsater, A., Elf, J., Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J, 15, 2017, 26.
Schastlivtsev, I., Lobastov, K., Tsaplin, S., Kanzafarova, I., Barinov, V., Laberko, L., et al. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: a single-center experience and review of the literature. Thromb Res 181 (2019), 24–28.
Houghton, D.E., Casanegra, A.I., Peterson, L.G., Cochuyt, J., Hodge, D.O., Vlazny, D., et al. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. Am J Hematol 95 (2020), 817–823.
Debourdeau, P., Farge, D., Beckers, M., Baglin, C., Bauersachs, R.M., Brenner, B., et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 11 (2013), 71–80.
Barco, S., Atema, J.J., Coppens, M., Serlie, M.J., Middeldorp, S., Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal. Blood Transfus 15 (2017), 369–377.
Engelberger, R.P., Kucher, N., Management of deep vein thrombosis of the upper extremity. Circulation 126 (2012), 768–773.
Mahmoud, O., Vikatmaa, P., Rasanen, J., Peltola, E., Sihvo, E., Vikatmaa, L., et al. Catheter-directed thrombolysis versus pharmacomechanical thrombectomy for upper extremity deep venous thrombosis: a cost-effectiveness analysis. Ann Vasc Surg 51 (2018), 246–253.
Guzzo, J.L., Chang, K., Demos, J., Black, J.H., Freischlag, J.A., Preoperative thrombolysis and venoplasty affords no benefit in patency following first rib resection and scalenectomy for subacute and chronic subclavian vein thrombosis. J Vasc Surg 52 (2010), 658–662.
Lee, J.A., Zierler, B.K., Zierler, R.E., The risk factors and clinical outcomes of upper extremity deep vein thrombosis. Vasc Endovascular Surg 46 (2012), 139–144.
Lugo, J., Tanious, A., Armstrong, P., Back, M., Johnson, B., Shames, M., et al. Acute Paget-Schroetter syndrome: does the first rib routinely need to be removed after thrombolysis?. Ann Vasc Surg 29 (2015), 1073–1077.
Schneider, D.B., Dimuzio, P.J., Martin, N.D., Gordon, R.L., Wilson, M.W., Laberge, J.M., et al. Combination treatment of venous thoracic outlet syndrome: open surgical decompression and intraoperative angioplasty. J Vasc Surg 40 (2004), 599–603.
Bosma, J., Vahl, A.C., Coveliers, H.M., Rauwerda, J.A., Wisselink, W., Primary subclavian vein thrombosis and its long-term effect on quality of life. Vascular 19 (2011), 327–332.
Taylor, J.M., Telford, R.J., Kinsella, D.C., Watkinson, A.F., Thompson, J.F., Long-term clinical and functional outcome following treatment for Paget-Schroetter syndrome. Br J Surg 100 (2013), 1459–1464.
Illig, K.A., Doyle, A.J., A comprehensive review of Paget-Schroetter syndrome. J Vasc Surg 51 (2010), 1538–1547.
Ageno, W., Beyer-Westendorf, J., Garcia, D.A., Lazo-Langner, A., McBane, R.D., Paciaroni, M., Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis 41 (2016), 129–143.
Tait, C., Baglin, T., Watson, H., Laffan, M., Makris, M., Perry, D., et al. Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 159 (2012), 28–38.
Thatipelli, M.R., McBane, R.D., Hodge, D.O., Wysokinski, W.E., Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol, 8, 2010 200–5.
Ma, K., Wells, P., Guzman, C., Anderson, D., Blostein, M., Hirsch, A., et al. A multicenter prospective study of risk factors and treatment of unusual site thrombosis. Thromb Res 144 (2016), 100–105.
Tufano, A., Ageno, W., Di Micco, P., Niglio, A., Rosa, V., Ballaz, A., et al. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thromb Res 164 (2018), 69–74.
Bjorck, M., Koelemay, M., Acosta, S., Bastos Goncalves, F., Kolbel, T., Kolkman, J.J., et al. Editor's Choice – Management of the diseases of mesenteric arteries and veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 53 (2017), 460–510.
Kamphuisen, P.W., Lee, A.Y., Catheter-related thrombosis: lifeline or a pain in the neck?. Hematology Am Soc Hematol Educ Program 2012 (2012), 638–644.
Baumann Kreuziger, L., Jaffray, J., Carrier, M., Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. Thromb Res 157 (2017), 64–71.
Geerts, W., Central venous catheter-related thrombosis. Hematology Am Soc Hematol Educ Program 2014 (2014), 306–311.
Verso, M., Agnelli, G., Bertoglio, S., Di Somma, F.C., Paoletti, F., Ageno, W., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23 (2005), 4057–4062.
Niers, T.M., Di Nisio, M., Klerk, C.P., Baarslag, H.J., Buller, H.R., Biemond, B.J., Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 5 (2007), 1878–1882.
Lee, A.Y., Levine, M.N., Butler, G., Webb, C., Costantini, L., Gu, C., et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24 (2006), 1404–1408.
Evans, R.S., Sharp, J.H., Linford, L.H., Lloyd, J.F., Tripp, J.S., Jones, J.P., et al. Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 138 (2010), 803–810.
Aw, A., Carrier, M., Koczerginski, J., McDiarmid, S., Tay, J., Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patients. Thromb Res 130 (2012), 323–326.
Saber, W., Moua, T., Williams, E.C., Verso, M., Agnelli, G., Couban, S., et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 9 (2011), 312–319.
Dentali, F., Gianni, M., Agnelli, G., Ageno, W., Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 6 (2008), 70–75.
Akl, E.A., Ramly, E.P., Kahale, L.A., Yosuico, V.E., Barba, M., Sperati, F., et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev, 10, 2014, CD006468.
Han, X., Yang, X., Huang, B., Yuan, L., Cao, Y., Low-dose versus high-dose heparin locks for hemodialysis catheters: a systematic review and meta-analysis. Clin Nephrol 86 (2016), 1–8.
Wang, Y., Ivany, J.N., Perkovic, V., Gallagher, M.P., Woodward, M., Jardine, M.J., Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. Cochrane Database Syst Rev, 4, 2016, CD009631.
Frank, D.A., Meuse, J., Hirsch, D., Ibrahim, J.G., van den Abbeele, A.D., The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis 10 (2000), 271–275.
Baumann Kreuziger, L., Onwuemene, O., Kolesar, E., Crowther, M., Lim, W., Systematic review of anticoagulant treatment of catheter-related thrombosis. Thromb Res 136 (2015), 1103–1109.
Baumann Kreuziger, L., Cote, L., Verhamme, P., Greenberg, S., Caprini, J., Munoz, F.J., et al. A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. J Vasc Surg Venous Lymphat Disord 3 (2015), 243–250.
Laube, E.S., Mantha, S., Samedy, P., Wills, J., Harnicar, S., Soff, G.A., Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban. Am J Hematol, 92, 2017 E9–10.
Davies, G.A., Lazo-Langner, A., Gandara, E., Rodger, M., Tagalakis, V., Louzada, M., et al. A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). Thromb Res 162 (2018), 88–92.
van Ommen, C.H., Peters, M., Venous thromboembolic disease in childhood. Semin Thromb Hemost 29 (2003), 391–404.
Raffini, L., Huang, Y.S., Witmer, C., Feudtner, C., Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 124 (2009), 1001–1008.
Andrew, M., David, M., Adams, M., Ali, K., Anderson, R., Barnard, D., et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 83 (1994), 1251–1257.
Male, C., Lensing, A.W.A., Palumbo, J.S., Kumar, R., Nurmeev, I., Hege, K., et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 7 (2020), e18–27.
Monagle, P., Cuello, C.A., Augustine, C., Bonduel, M., Brandao, L.R., Capman, T., et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2 (2018), 3292–3316.
Monagle, P., Chan, A.K.C., Goldenberg, N.A., Ichord, R.N., Journeycake, J.M., Nowak-Gottl, U., et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e737S–801S.
Monagle, P., Lensing, A.W.A., Thelen, K., Martinelli, I., Male, C., Santamaria, A., et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol 7 (2020), e18–27.
Bates, S.M., Ginsberg, J.S., How we manage venous thromboembolism during pregnancy. Blood 100 (2002), 3470–3478.
Bates, S.M., Greer, I.A., Pabinger, I., Sofaer, S., Hirsh, J., Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 2008 844S–86S.
Greer, I.A., Pregnancy complicated by venous thrombosis. N Engl J Med 373 (2015), 540–547.
Abdul Sultan, A., Grainge, M.J., West, J., Fleming, K.M., Nelson-Piercy, C., Tata, L.J., Impact of risk factors on the timing of first postpartum venous thromboembolism: a population-based cohort study from England. Blood 124 (2014), 2872–2880.
Kamel, H., Navi, B.B., Sriram, N., Hovsepian, D.A., Devereux, R.B., Elkind, M.S., Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 370 (2014), 1307–1315.
Knight, M., Nair, M., Shah, A., Noor, N., Acosta, C., Maternal Mortality and Morbidity in the UK 2009–12: Surveillance and Epidemiology. 2014, National Perinatal Epidemiology Unit, University of Oxford, Oxford.
CEMACH. The Confidential Enquiry into Maternal and Child Health (CEMACH) – Saving Mothers’ Lives: Reviewing Maternal Deaths to Make Motherhood Safer 2003–2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom, 2007, CEMACH, London.
Hunt, B.J., Hemostasis at extremes of body weight. Semin Thromb Hemost 44 (2018), 632–639.
Royal College of Obstetricians and Gynecologists. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management. Green-Top Guideline No. 37b. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37b.pdf.
Chan, W.S., Spencer, F.A., Ginsberg, J.S., Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ 182 (2010), 657–660.
Ouriel, K., Green, R.M., Greenberg, R.K., Clair, D.G., The anatomy of deep venous thrombosis of the lower extremity. J Vasc Surg 31 (2000), 895–900.
Goodacre, S., Horspool, K., Shephard, N., Pollard, D., Hunt, B.J., Fuller, G., et al. Selecting pregnant or postpartum women with suspected pulmonary embolism for diagnostic imaging: the DiPEP diagnostic study with decision-analysis modelling. Health Technol Assess 22 (2018), 1–230.
Chan, W.S., Lee, A., Spencer, F.A., Crowther, M., Rodger, M., Ramsay, T., et al. Predicting deep venous thrombosis in pregnancy: out in “LEFt” field?. Ann Intern Med 151 (2009), 85–92.
Righini, M., Jobic, C., Boehlen, F., Broussaud, J., Becker, F., Jaffrelot, M., et al. Predicting deep venous thrombosis in pregnancy: external validation of the LEFT clinical prediction rule. Haematologica 98 (2013), 545–548.
Clements, H., Duncan, K.R., Fielding, K., Gowland, P.A., Johnson, I.R., Baker, P.N., Infants exposed to MRI in utero have a normal paediatric assessment at 9 months of age. Br J Radiol 73 (2000), 190–194.
Robertson, L., Wu, O., Langhorne, P., Twaddle, S., Clark, P., Lowe, G.D., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2006), 171–196.
Greer, I.A., Nelson-Piercy, C., Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 (2005), 401–407.
Richter, C., Sitzmann, J., Lang, P., Weitzel, H., Huch, A., Huch, R., Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol 52 (2001), 708–710.
Chaudhary, R.K., Nepal, C., Khanal, N., Pathak, R., Giri, S., Bhatt, V.R., Management and outcome of heparin-induced thrombocytopenia in pregnancy: a systematic review. Cardiovasc Hematol Agents Med Chem 13 (2015), 92–97.
Tang, A.W., Greer, I., A systematic review on the use of new anticoagulants in pregnancy. Obstet Med 6 (2013), 64–71.
Beyer-Westendorf, J., Michalski, F., Tittl, L., Middeldorp, S., Cohen, H., Abdul Kadir, R., et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost 116 (2016), 651–658.
Harris, S.A., Velineni, R., Davies, A.H., Inferior vena cava filters in pregnancy: a systematic review. J Vasc Interv Radiol 27 (2016), 354–360.
McColl, M.D., Ellison, J., Greer, I.A., Tait, R.C., Walker, I.D., Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol 108 (2000), 272–274.
Wik, H.S., Jacobsen, A.F., Sandvik, L., Sandset, P.M., Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. J Thromb Haemost 10 (2012), 840–847.
Prandoni, P., Lensing, A.W., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002), 3484–3488.
Cohen, A.T., Katholing, A., Rietbrock, S., Bamber, L., Martinez, C., Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 117 (2017), 57–65.
Ay, C., Pabinger, I., Cohen, A.T., Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 117 (2017), 219–230.
Posch, F., Konigsbrugge, O., Zielinski, C., Pabinger, I., Ay, C., Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 136 (2015), 582–589.
Kirkilesis, G.I., Kakkos, S.K., Tsolakis, I.A., Editor's Choice – A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg 57 (2019), 685–701.
Raskob, G.E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378 (2018), 615–624.
Kraaijpoel, N., Di Nisio, M., Mulder, F.I., van Es, N., Beyer-Westendorf, J., Carrier, M., et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost 118 (2018), 1439–1449.
Young, A.M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36 (2018), 2017–2023.
McBane, R. II, Wysokinski, W.E., Le-Rademacher, J.G., Zemla, T., Ashrani, A., Tafur, A., et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18 (2020), 411–421.
Agnelli, G., Becattini, C., Meyer, G., Munoz, A., Huisman, M.V., Connors, J.M., et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382 (2020), 1599–1607.
Elalamy, I., Mahe, I., Ageno, W., Meyer, G., Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. J Thromb Haemost 15 (2017), 848–857.
Romualdi, E., Ageno, W., Management of recurrent venous thromboembolism in cancer patients. Thromb Res 140:Suppl. 1 (2016), S128–S131.
Lippi, G., Favaloro, E.J., Venous and arterial thromboses: two sides of the same coin?. Semin Thromb Hemost 44 (2018), 239–248.
Montagnana, M., Lippi, G., Danese, E., An overview of thrombophilia and associated laboratory testing. Methods Mol Biol 1646 (2017), 113–135.
Garcia, D., Erkan, D., Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 379 (2018), 2010–2021.
Kearon, C., Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism. Curr Opin Hematol 19 (2012), 363–370.
Lijfering, W.M., Veeger, N.J., Middeldorp, S., Hamulyak, K., Prins, M.H., Buller, H.R., et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 114 (2009), 2031–2036.
Tzoran, I., Papadakis, M., Brenner, B., Fidalgo, A., Rivas, A., Wells, P.S., et al. Outcome of patients with venous thromboembolism and factor V Leiden or prothrombin 20210 carrier mutations during the course of anticoagulation. Am J Med 130 (2017), 482.e1–482.e9.
Mahmoodi, B.K., Brouwer, J.L., Ten Kate, M.K., Lijfering, W.M., Veeger, N.J., Mulder, A.B., et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost 8 (2010), 1193–1200.
Rossi, E., Ciminello, A., Za, T., Betti, S., Leone, G., De Stefano, V., In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. Thromb Haemost 106 (2011), 646–654.
Casini, A., Blondon, M., Lebreton, A., Koegel, J., Tintillier, V., de Maistre, E., et al. Natural history of patients with congenital dysfibrinogenemia. Blood 125 (2015), 553–561.
Kreidy, R., Factor V-Leiden mutation: a common risk factor for venous thrombosis among Lebanese patients. Thrombosis, 2012, 2012, 380681.
Bertoletti, L., Benhamou, Y., Bejot, Y., Marechaux, S., Cheggour, S., Aleil, B., et al. Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: a narrative review. Blood Rev 32 (2018), 272–279.
Undas, A., Goralczyk, T., Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood Coagul Fibrinolysis 28 (2017), 438–442.
Signorelli, F., Nogueira, F., Domingues, V., Mariz, H.A., Levy, R.A., Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 35 (2016), 801–805.
Elsebaie, M.A.T., van Es, N., Langston, A., Buller, H.R., Gaddh, M., Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost 17 (2019), 645–656.
Pengo, V., Denas, G., Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): a personal perspective. Thromb Res 169 (2018), 35–40.
Skelley, J.W., White, C.W., Thomason, A.R., The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis 43 (2017), 24–30.
Dufrost, V., Risse, J., Reshetnyak, T., Satybaldyeva, M., Du, Y., Yan, X.X., et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 17 (2018), 1011–1021.
Pengo, V., Denas, G., Zoppellaro, G., Jose, S.P., Hoxha, A., Ruffatti, A., et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132 (2018), 1365–1371.
Malec, K., Broniatowska, E., Undas, A., Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus 29 (2020), 37–44.
Ordi-Ros, J., Saez-Comet, L., Perez-Conesa, M., Vidal, X., Riera-Mestre, A., Castro-Salomo, A., et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 171 (2019), 685–694.
Woller, S.C., Stevens, S.M., Kaplan, D.A., Branch, D.W., Aston, V.T., Wilson, E.L., et al. Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS). Clin Appl Thromb Hemost 22 (2016), 239–247.
De Maeseneer, M.G., Hertoghs, M., Lauwers, K., Koeyers, W., de Wolf, M., Wittens, C., Chronic venous insufficiency in patients with absence of the inferior vena cava. J Vasc Surg Venous Lymphat Disord 1 (2013), 39–44.
Broholm, R., Jorgensen, M., Just, S., Jensen, L.P., Baekgaard, N., Acute iliofemoral venous thrombosis in patients with atresia of the inferior vena cava can be treated successfully with catheter-directed thrombolysis. J Vasc Interv Radiol 22 (2011), 801–805.
Rattazzi, M., Villalta, S., De Lucchi, L., Sponchiado, A., Galliazzo, S., Faggin, E., et al. Chronic kidney disease is associated with increased risk of venous thromboembolism recurrence. Thromb Res 160 (2017), 32–37.
Di Minno, M.N., Ambrosino, P., Dentali, F., Safety of warfarin in “high-risk” populations: a meta-analysis of randomized and controlled trials. Thromb Res 150 (2017), 1–7.
Buller, H.R., Davidson, B.L., Decousus, H., Gallus, A., Gent, M., Piovella, F., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004), 867–873.
Woodruff, S., Feugere, G., Abreu, P., Heissler, J., Ruiz, M.T., Jen, F., A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. J Thromb Thrombolysis 42 (2016), 494–504.
Goldhaber, S.Z., Schulman, S., Eriksson, H., Feuring, M., Fraessdorf, M., Kreuzer, J., et al. Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II. Thromb Haemost 117 (2017), 2045–2052.
Di Nisio, M., Vedovati, M.C., Riera-Mestre, A., Prins, M.H., Mueller, K., Cohen, A.T., et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. Thromb Haemost 116 (2016), 739–746.
Costa, O.S., Beyer-Westendorf, J., Ashton, V., Milentijevic, D., Moore, K.T., Bunz, T.J., et al. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. J Thromb Thrombolysis, 2020, 10.1007/s11239-020-02199-0 [in press].
